Exane Derivatives’s BioMarin Pharmaceuticals BMRN Stock Holding History

Exane Derivatives’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$122K	Sell	1,473 -416	-22%	-$33.1K	0.07%	246
2022 Q1	$146K	Sell	1,889 -220	-10%	-$18.4K	0.04%	407
2021 Q4	$186K	Sell	2,109 -667	-24%	-$55K	0.05%	351
2021 Q3	$215K	Sell	2,776 -293	-10%	-$23.1K	0.05%	380
2021 Q2	$250K	Buy	3,069 +233	+8%	+$18.5K	0.06%	341
2021 Q1	$214K	Buy	2,836 +978	+53%	+$79.9K	0.06%	288
2020 Q4	$163K	Buy	1,858 +1,130	+155%	+$89.6K	0.05%	336
2020 Q3	$55.4K	Hold	728	–	–	0.02%	370
2020 Q2	$89.8K	Hold	728	–	–	0.02%	310
2020 Q1	$61.5K	Sell	728 -165	-18%	-$14.2K	0.02%	340
2019 Q4	$79.3K	Hold	893	–	–	0.01%	337
2019 Q3	$60.2K	Sell	893 -5	-0.6%	-$385	0.01%	357
2019 Q2	$76.9K	Buy	898 +1	+0.1%	+$86	0.01%	357
2019 Q1	$79.7K	Buy	897 +430	+92%	+$39.9K	0.02%	318
2018 Q4	$39.8K	Buy	467 +454	+3,492%	+$43.2K	0.01%	379
2018 Q3	$1.26K	Sell	13 -1,315	-99%	-$131K	﹤0.01%	523
2018 Q2	$125K	Sell	1,328 -35	-3%	-$3.06K	0.02%	308
2018 Q1	$108K	Buy	1,363 +1,331	+4,159%	+$114K	0.02%	292
2017 Q4	$2.85K	Sell	32 -140	-81%	-$12.2K	﹤0.01%	445
2017 Q3	$16K	Buy	+172	New	+$15.2K	﹤0.01%	364

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Exane Derivatives's BMRN Position: Q2 2022 in Review

Exane Derivatives reduced its BioMarin Pharmaceuticals (BMRN) stake by 22% in Q2 2022, selling an estimated $33.1K and leaving 1,473 shares worth $122K. The position accounts for 0.07% of the portfolio, ranked #246.

Exane Derivatives first reported a position in BMRN in Q3 2017 and has held it in 20 quarters since. The position peaked at $250K in Q2 2021. 543 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Exane Derivatives held 1,473 shares of BioMarin Pharmaceuticals worth $122K as of Q2 2022.
Exane Derivatives sold 416 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $33.1K.
BioMarin Pharmaceuticals made up 0.07% of Exane Derivatives's portfolio in Q2 2022, its #246 holding.
Exane Derivatives first reported a position in BioMarin Pharmaceuticals in Q3 2017 and has held it in 20 quarters since.
Exane Derivatives's BioMarin Pharmaceuticals position peaked at $250K in Q2 2021.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.